Alector, Inc. (ALEC, Financial), a clinical-stage biopharmaceutical company, experienced a significant stock decline of 5.02%. The stock is currently priced at $2.46 per share, with a trading volume of 1.44 million shares and a turnover rate of 1.47%. The stock's amplitude reached 6.53%.
Recent financial reports show Alector's revenue at $15.34 million, a net loss of $42.22 million, and an earnings per share of -$0.43, resulting in a price-to-earnings ratio of -1.44. Among 11 rating institutions, 73% recommend buying, 9% suggest holding, and 18% advise selling the stock.
Within the biotechnology sector, which saw an overall increase of 0.10%, stocks like Senti Biosciences, Purple Biotech, and Quoin Pharmaceuticals exhibited notable activity, with Purple Biotech and Senti Biosciences showing high turnover rates and significant price swings.
